Acta Neuropathologica Communications (Jun 2021)

Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease

  • Pamela J. McMillan,
  • Timothy J. Strovas,
  • Misa Baum,
  • Brooke K. Mitchell,
  • Randall J. Eck,
  • Nzinga Hendricks,
  • Jeanna M. Wheeler,
  • Caitlin S. Latimer,
  • C. Dirk Keene,
  • Brian C. Kraemer

DOI
https://doi.org/10.1186/s40478-021-01219-1
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Several conserved nuclear RNA binding proteins (sut-1, sut-2, and parn-2) control tau aggregation and toxicity in C. elegans, mice, and human cells. MSUT2 protein normally resides in nuclear speckles, membraneless organelles composed of phase-separated RNAs and RNA-binding proteins that mediate critical steps in mRNA processing including mRNA splicing. We used human pathological tissue and transgenic mice to identify Alzheimer’s disease-specific cellular changes related to nuclear speckles. We observed that nuclear speckle constituent scaffold protein SRRM2 is mislocalized and accumulates in cytoplasmic lesions in AD brain tissue. Furthermore, progression of tauopathy in transgenic mice is accompanied by increasing mislocalization of SRRM2 from the neuronal nucleus to the soma. In AD brain tissue, SRRM2 mislocalization associates with increased severity of pathological tau deposition. These findings suggest potential mechanisms by which pathological tau impacts nuclear speckle function in diverse organisms ranging from C. elegans to mice to humans. Future translational studies aimed at restoring nuclear speckle homeostasis may provide novel candidate therapeutic targets for pharmacological intervention.

Keywords